Adage Capital Partners’s TScan Therapeutics TCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,500,000
| Closed | -$4.83M | – | 945 |
|
|
2025
Q1 | $4.83M | Hold |
3,500,000
| – | – | 0.01% | 702 |
|
|
2024
Q4 | $10.6M | Sell |
3,500,000
-900,000
| -20% | -$2.74M | 0.02% | 588 |
|
|
2024
Q3 | $21.9M | Hold |
4,400,000
| – | – | 0.04% | 428 |
|
|
2024
Q2 | $25.7M | Buy |
4,400,000
+500,000
| +13% | +$2.93M | 0.05% | 370 |
|
|
2024
Q1 | $31M | Hold |
3,900,000
| – | – | 0.06% | 345 |
|
|
2023
Q4 | $22.7M | Sell |
3,900,000
-100,000
| -3% | -$583K | 0.05% | 393 |
|
|
2023
Q3 | $10.2M | Hold |
4,000,000
| – | – | 0.02% | 556 |
|
|
2023
Q2 | $10M | Buy |
4,000,000
+3,450,000
| +627% | +$8.63M | 0.02% | 571 |
|
|
2023
Q1 | $1.16M | Hold |
550,000
| – | – | ﹤0.01% | 791 |
|
|
2022
Q4 | $853K | Hold |
550,000
| – | – | ﹤0.01% | 845 |
|
|
2022
Q3 | $1.68M | Hold |
550,000
| – | – | ﹤0.01% | 865 |
|
|
2022
Q2 | $1.73M | Hold |
550,000
| – | – | ﹤0.01% | 889 |
|
|
2022
Q1 | $1.54M | Hold |
550,000
| – | – | ﹤0.01% | 915 |
|
|
2021
Q4 | $2.48M | Buy |
550,000
+53,417
| +11% | +$240K | ﹤0.01% | 861 |
|
|
2021
Q3 | $4.14M | Buy |
+496,583
| New | +$4.14M | 0.01% | 850 |
|